Zymergen Inc. (NasdaqGS:ZY) acquired Lodo Therapeutics Corp. from Accelerator Life Science Partners I, managed by Accelerator Life Science Partners and others on May 16, 2021. All employees of Lodo Therapeutics Corp. will join Zymergen Inc.

Zymergen Inc. (NasdaqGS:ZY) completed the acquisition of Lodo Therapeutics Corp. from Accelerator Life Science Partners I, managed by Accelerator Life Science Partners and others for $25.9 million on May 16, 2021. The purchase price for the acquisition was $25.3 million, substantially all of which was non-cash consideration. The non-cash consideration consisted of 774,402 shares of the Zymergen's common stock. As part of the acquisition, Zymergen acquired $1.8 million of cash and cash equivalents.